Drug delivery training devices that help patients learn to administer their injection medications

Joe Reynolds leverages the knowledge of the pharmaceutical and medical device industries to derive insights and maximize value for all members of the Noble healthcare team. His experience includes work with various consumer and healthcare brands. Joe holds a Bachelor of Science in Business from the University of Central Florida, a Master’s of Science in Marketing from the University of South Florida and a Master’s of Science in Pharmacy from the University of Florida.

Read More

Phase 3 Study of Recurrent Metastatic HNSCC with KEYTRUDA

As of June 11, 2019, Merck’s KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (CPS ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression. Returning guest Dr. Danny Rischin, Director of the Department of Medical Oncology, Peter MacCallum Cancer Centre (Melbourne, Australia) discusses the final analysis of the Phase 3 KEYNOTE-048, KEYTRUDA study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Read More